GGrantIndex
← Leaderboards

Brian Matthew Wolpin

Dana-Farber Cancer Inst

$8,665,523
Attributed
$10,341,566
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY200925
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,579,077 · 7

By mechanism

U01$7,839,087 · 1
P50$3,678,394 · 3
K07$889,641 · 1
P30$171,955 · 2

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Top investigators on “Collaborations

Research focus

CollaborationsCancer CenterResearch PersonnelMalignant NeoplasmsCancer EtiologyCessation Of LifeUnited StatesPancreasMalignant Neoplasm Of PancreasScienceBiological MarkersInvestigationResourcesInnovationTumorCell Free DnaPancreatic Ductal AdenocarcinomaGenomicsTechnologyProgramsScreeningDiagnosisFutureEvaluation

Grant awards (25)

Altered metabolism and machine learning for pancreatic cancer early detection$828,138
U01 · FY2025 · CA · contact PI
Program 32: Gastrointestinal Malignancies$46,965
P30 · FY2025 · CA · contact PI
Altered metabolism and machine learning for pancreatic cancer early detection$786,734
U01 · FY2024 · CA · contact PI
Program 32: Gastrointestinal Malignancies$40,758
P30 · FY2024 · CA · contact PI
Altered metabolism and machine learning for pancreatic cancer early detection$811,576
U01 · FY2023 · CA · contact PI
Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma$331,080
P50 · FY2023 · CA · contact PI
Program 32: Gastrointestinal Malignancies$42,116
P30 · FY2023 · CA · contact PI
Altered metabolism and machine learning for pancreatic cancer early detection$925,639
U01 · FY2022 · CA · contact PI
Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma$366,382
P50 · FY2022 · CA · contact PI
Program 32: Gastrointestinal Malignancies$42,116
P30 · FY2022 · CA · contact PI
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection$748,441
U01 · FY2021 · CA · contact PI
Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma$166,489
P50 · FY2021 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$2,237,511
P50 · FY2020 · CA · contact PI
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection$781,620
U01 · FY2020 · CA · contact PI
Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma$245,850
P50 · FY2020 · CA · contact PI
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection$762,351
U01 · FY2019 · CA · contact PI
Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma$331,082
P50 · FY2019 · CA · contact PI
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection$602,403
U01 · FY2018 · CA · contact PI
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection$794,139
U01 · FY2017 · CA · contact PI
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection$798,046
U01 · FY2016 · CA · contact PI
Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer$178,110
K07 · FY2013 · CA · contact PI
Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer$178,110
K07 · FY2012 · CA · contact PI
Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer$177,777
K07 · FY2011 · CA · contact PI
Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer$177,867
K07 · FY2010 · CA · contact PI
Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer$177,777
K07 · FY2009 · CA · contact PI